Pernix Therapeutics Holdings Inc. has introduced the Omeclamox-Pak, the first product in its gastroenterology portfolio.


Pernix Therapeutics, Omeclamox-Pak, gastroenterology, omeprazole, clarithromycin, amoxicillin, Helicobacter pylori, H. pylori, duodenal ulcer disease, triple combination medication, Cooper Collins, Chuck Hrushka




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Pernix to release first gastroenterology offering

May 17th, 2012

THE WOODLANDS, Texas – Pernix Therapeutics Holdings Inc. has introduced the Omeclamox-Pak, the first product in its gastroenterology portfolio.

The specialty pharmaceutical company said this week that the Omeclamox-Pak is a 10-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease in adults.

Plans call for the product to become available by prescription in July, according to Pernix.

"The introduction of Omeclamox-Pak is an important milestone for Pernix, as the company's prescription portfolio continues to broaden with the addition of a new branded product that will be launched by our newly established gastroenterology sales force," commented Cooper Collins, president and chief executive officer of Pernix. "We are pleased to offer patients suffering from H. pylori infection and duodenal ulcers with a new treatment option."

A triple combination medication, Omeclamox-Pak is a taken orally twice a day. It includes a proton pump inhibitor (omeprazole) and two broad-spectrum antibiotics (clarithromycin tablets and amoxicillin capsules).

"We have recruited a new sales force and established a targeted marketing program that will reach gastroenterology professionals in the coming months," stated Chuck Hrushka, vice president of sales and marketing for Pernix. "We anticipate physicians and their patients will welcome the short, 10-day dosing regimen, especially when compared to other treatments."

Advertisement